Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

NOX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 35.21%

Insider Buying (Last 12 Months): A$80,108.04

Insider Selling (Last 12 Months): A$0.00

Noxopharm Insider Trading History Chart

Noxopharm Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 05/13/2020 01:00 AM ET

Move Your Money Before May 22

From Stansberry Research | Ad

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Noxopharm Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/14/2023	Frederick (Fred) Bart	Insider	Buy	253,001	A$0.04	A$9,108.04
6/29/2023	Frederick (Fred) Bart	Insider	Transfer	3,080,189	A$0.06	A$169,410.40
5/9/2023	Frederick (Fred) Bart	Insider	Buy	500,000	A$0.04	A$21,000.00
5/4/2023	Frederick (Fred) Bart	Insider	Buy	1,000,000	A$0.05	A$50,000.00
12/15/2022	Frederick (Fred) Bart	Insider	Expiry	3,000,000	A$0.15	A$435,000.00
12/1/2021	Graham Kelly	Insider	Expiry	37,037	A$0.44	A$16,296.28
5/31/2021	Boris Patkin	Insider	Issued	250,000	A$0.74	A$183,750.00
4/29/2021	Boris Patkin	Insider	Cancelled	250,000	A$0.60	A$150,000.00

Move Your Money Before May 22

From Stansberry Research | Ad

Here's where Dr. David Eifrig says to move your money immediately.

SEC Filings (Institutional Ownership Changes) for Noxopharm (ASX:NOX)

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,231,749 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Who are the company insiders with the largest holdings of Noxopharm?: Noxopharm's top insider shareholders include:
Frederick (Fred) Bart (Insider)
Learn More about top insider investors at Noxopharm.